Thus, there has been one experimental medicine trial using a fully humanized anti-TNF monoclonal antibody, adalimumab, which was originally designed to reduce pain and swelling due to certain types of arthritis, to treat a group of 10 athletes with symptomatic unilateral tendinopathy for more than 6 months (Fredberg and Ostgaard 2009). The gene discussed is TNF; the disease is arthritic joint disease.